Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...
Genomics company 10x and Harvard University have agreed to resolve a patent lawsuit against 10x's rival Vizgen four days into ...
Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.
TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The ...
As investors seek high-growth opportunities in the evolving crypto market, projects with strong fundamentals and real-world ...
Vitalik Buterin urges a 10X Ethereum scaling boost for L1 to enhance security, reduce L2 risks, and streamline application ...
Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...
Wall Street Pepe Closes Presale, Projecting 10x Returns Wall Street Pepe ($WEPE) has triumphantly wrapped up its presale ...